ACRV · Acrivon Therapeutics, Inc. Common Stock

0001193125-26-221634

Summary

Operating losses narrowed modestly through cost discipline primarily in employee-related expenses including stock-based compensation, though cash burn accelerated due to lower non-cash items; existing cash plus ATM proceeds funds operations into Q3 2027 amid expected cost increases.

Key takeaways

Operating income improved 8.1% to -$19.9M from -$21.7M year-over-year.
Net income narrowed 3.2% to -$19.0M from -$19.7M prior year.
Diluted EPS improved 3.9% to -$0.49 from -$0.51.
Net cash used in operating activities increased to -$20.5M from -$19.5M.
Free cash flow was -$20.6M after $14K capital expenditures.

Full analysis

Looking ahead, research and development and general and administrative costs are expected to increase with planned research, clinical activities, public company operations, headcount growth, and services to support drug candidate development. Clinical development costs are anticipated to rise significantly with ongoing and planned trials, underscoring the need for disciplined capital management to extend the runway while advancing the pipeline.